Practical management of natural killer/T-cell lymphoma

Current Opinion in Oncology

Volumn 24, Issue 5, 2012, Pages 480-486

  Tse, Eric ^a   Kwong, Yok Lam ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epstein Barr virus; extranodal lymphoma; nasal lymphoma; natural killer cell; SMILE

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE; VIRUS DNA;

ADVANCED CANCER; AGE DISTRIBUTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; EARLY CANCER; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; NATURAL KILLER CELL; NK T CELL LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEX RATIO; TREATMENT RESPONSE; VIRUS LOAD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL;

EID: 84865505741     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283556142     Document Type: Review

References (47)

1. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19:2186-2194.
2. Gill H, Liang RH, Tse E. Extranodal natural-killer/t-cell lymphoma, nasal type. Adv Hematol 2010; 2010:627401.
3. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC. Extrannodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 285-288.
4. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood 2009; 113:3931-3937.
5. Tse E, Leung R, Khong PL, et al. Nonnasal natural killer cell lymphoma: not nonnasal after all. Ann Hematol 2009; 88:185-187.
6. Chan JK, Yip TT, Tsang WY, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18:938-946. (Pubitemid 24260234)
7. Huang Y, de Reynies A, de Leval L, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115:1226-1237.
8. Iqbal J, Weisenburger DD, Chowdhury A, et al. Natural killer cell lymphoma shares strikingly similar molecular features with a group of nonhepatosplenic gammadelta T-cell lymphoma and is highly sensitive to a novel aurora kinase a inhibitor in vitro. Leukemia 2011; 25:348-358.
9. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011; 223:496-510.
10. Ng SB, Yan J, Huang G, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011; 118:4919-4929.
11. Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157:1803-1809.
12. Kallies A, Carotta S, Huntington ND, et al. A role for blimp1 in the transcriptional network controlling natural killer cell maturation. Blood2011;117:1869-1879.
13. Karube K, Nakagawa M, Tsuzuki S, et al. Identification of foxo3 and prdm1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118:3195-3204.
14. Kucuk C, Iqbal J, Hu X, et al. Prdm1 is a tumor suppressor gene in natural killer cell malignancies. Proc Natl Acad Sci USA 2011; 108:20119-20124.
15. Khong PL, Pang CB, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008; 87:613-621.
16. Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B-and T-cell lymphomas. Clin Nucl Med 2010; 35:571-575.
17. Lee J, Suh C, Huh J, et al. Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/Tcell lymphoma, nasal-type. Clin Cancer Res 2007; 13:3250-3254. (Pubitemid 46944909)
18. MacDonald SL,Mulroy L, Wilke DR, Burrell S. PET/CT aids the staging of and radiotherapy planning for early-stage extranodal natural killer/T-cell lymphoma, nasal type: a case series. Radiat Oncol 2011; 6:182.
19. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103:216-221.
20. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasaltype: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612-618. (Pubitemid 46630424)
21. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113:3147-3153.
22. Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010; 21:1032-1040.
23. Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBVpositive lymphomas in immunocompetent patients. Blood 2004; 104:243-249. (Pubitemid 38879864)
24. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003; 63:2028-2032. (Pubitemid 36538602)
25. Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011; 118:6018-6022.
26. Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and naturalkiller-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10:1093-1101.
27. Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasaltype NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112:3057-3064.
28. Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 2009; 114:4771-4776.
29. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study jcog0211. J Clin Oncol 2009; 27:5594-5600.
30. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by vipd chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009; 27:6027-6032.
31. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of p-glycoprotein/mdr1 by nasal T-cell lymphoma cells. Cancer 1995; 76:2351-2356.
32. Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant 2009; 44:709-714.
33. Ishida F, Nishina S, Asano N, et al. Late relapse of extranodal natural killer/T cell lymphoma, nasal type, after more than ten years. Leuk Lymphoma 2010; 51:171-173.
34. Au WY, Kim SJ, Yiu HH, et al. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission. Am J Hematol 2010; 85:362-363.
35. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99:1016-1020. (Pubitemid 351997606)
36. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol 2011; 29:4410-4416.
37. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte society. Blood 1999; 93:1869-1874. (Pubitemid 29128488)
38. Jaccard A, Petit B, Girault S, et al. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009; 20:110-116.
39. Obama K, Tara M, Niina K. L-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 2003; 78:248-250. (Pubitemid 37288512)
40. Yong W, Zheng W, Zhu J, et al. L-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009; 88:647-652.
41. Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011; 117:1834-1839.
42. Kim BS, Kim DW, Im SA, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 2009; 20:121-128.
43. Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/t cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14:1356-1364.
44. Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14:1673-1676. (Pubitemid 37455818)
45. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130:561-567. (Pubitemid 43899760)
46. Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008; 83:721-727.
47. Kako S, Izutsu K, Oshima K, et al. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82:937-939. (Pubitemid 47502704)